Background: Hypertension is prevalent in 35%-46% of the general population; 1% of them experience accelerated hypertension. Among patients with accelerated hypertension, acute worsening of renal functions occur in 22%-55%. Morbidity and mortality rates are high. Partial renal recovery is seen in some, while others rapidly progress to end-stage renal disease.
Methods: Patients who presented with accelerated hypertension, renal dysfunction, and had undergone renal biopsy were evaluated and their clinical profile was analyzed. Those who became dialysis dependent were excluded from further follow-up. Study outcome were blood pressure control, renal functions, requirement of renal replacement and mortality.
Results: Of the 30 patients evaluated, age at presentation was 41.2 ± 15.46 years and 26 (86.7%) were males, 10 (33%) had presented with nonspecific complaints. Mean duration of hypertension and blood pressure were 21.93 months and 196 ± 20.8/129 ± 12.4 mmHg, respectively. Glomerulonephritis and hypertensive nephrosclerosis had similar characteristics except proteinuria ( = 0.04). Average follow-up ( = 25) duration was 3.69 years (range: 0.05-9.6). At the end of study, 6 were dialysis dependent, while in others, mean e-GFR was 23.96 ml/min/1.73 m. Poor renal prognosis was predicted by glomerulonephritis (relative risk-4.6) and degree of interstitial fibrosis. Five-year patient and renal survival were 94.4% and 71.9%, respectively.
Conclusion: Accelerated hypertension occurs among patients with both primary and secondary hypertension. It leaves permanent renal sequelae. Though some patients recover renal function partially, further progression is rapid, especially among those with chronic glomerulonephritis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023030 | PMC |
http://dx.doi.org/10.4103/ijn.IJN_332_19 | DOI Listing |
Alzheimers Dement
December 2024
University of Virginia, Charlottesville, VA, USA.
Background: Seizures are a common co-morbidity of dementia and are associated with accelerated cognitive decline. However, the impact of recurrent versus remote seizures on mortality outcomes in people with dementia (PWD) has not been studied. The purpose of our study is to fill this knowledge gap.
View Article and Find Full Text PDFMol Carcinog
January 2025
Department of Otorhinolaryngology, The Third Affiliated Hospital of ZunYi Medical University/First People's Hospital of Zunyi, Zunyi, China.
This study aimed to explore PTPN2 expression levels in Hypopharyngeal Squamous Cell Carcinoma (HPSCC) tissues and their relationship with the clinical characteristics and prognosis of HPSCC patients. PTPN2, a protein tyrosine phosphatase, has recently emerged as a promising target for cancer immunotherapy, and in many previous studies, PTPN2 may have a significant role in the growth, differentiation, metabolism and immune response of head and neck malignant tumors. In this study, PTPN2 expression in Head and Neck Squamous Cell Carcinoma (HNSCC) and other cancer tissues was analyzed using datasets derived from the Sangerbox database.
View Article and Find Full Text PDFSurg Neurol Int
December 2024
Department of Medicine, University of Hawai'i at Mānoa, John A. Burns School of Medicine, Honolulu, Hawaii, USA.
Background: One avenue to improve outcomes among brain tumor patients involves the mitigation of healthcare disparities. Investigating clinical differences among brain tumors across socioeconomic and demographic strata, such can aid in healthcare disparity identification and, by extension, outcome improvement.
Methods: Utilizing a racially diverse population from Hawaii, 323 cases of brain tumors (meningiomas, gliomas, schwannomas, pituitary adenomas, and metastases) were matched by age, sex, and race to 651 controls to investigate the associations between tumor type and various demographic, socioeconomic, and medical comorbidities.
Front Cardiovasc Med
December 2024
Department of Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Introduction: Based on office blood pressure (BP) values, hypertension is categorized into three stages: stage 1 (140-159/90-99 mmHg), stage 2 (160-179/100-109 mmHg), and stage 3 (≥180/≥110 mmHg). Malignant hypertension (MHT) is characterized by extreme BP elevation (systolic blood pressure above 200 mmHg and diastolic blood pressure above 130 mmHg) and acute microvascular damage affecting various organs, particularly the retinas, brain, and kidneys.
Objectives: The pathogenesis, predisposing variables, therapy, and preventive strategies for MHT were examined in this review.
J Gerontol A Biol Sci Med Sci
January 2025
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Background: The association between subclinical cardiovascular disease (CVD) and cognitive decline in hypertensive adults and the underlying brain pathologies remain unclear. It is also undetermined whether intensifying blood pressure (BP) treatment slows down cognitive decline associated with subclinical CVD.
Methods: We conducted a post hoc analysis of the Systolic Blood Pressure Intervention Trial.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!